TL;DR
- A Field Alert Report (FAR) is a mandatory notice that NDA and ANDA holders must send FDA within 3 working days of learning about certain distributed-product quality problems (21 CFR 314.81(b)(1); FDA: Field Alert Reports).
- The clock starts the day you receive the information, not the day you confirm it's a real problem (FDA Guidance: Field Alert Report Submission Q&A, §3a).
- Missing the deadline isn't just a paperwork lapse. It's a standalone violation of section 505(k) of the FD&C Act, 21 U.S.C. § 355(k), which is a prohibited act under section 301(e), 21 U.S.C. § 331(e) (FDA Guidance, §3b).
- A September 2025 warning letter to Somerset Therapeutics shows what a severe miss looks like: visibly cloudy vials identified around September 30, 2024, and no FAR submitted until after FDA's February 10-21, 2025 inspection had already closed (FDA Warning Letter 320-25-106).
- Not every complaint triggers a FAR. Only information meeting the specific criteria in 21 CFR 314.81(b)(1)(i)-(ii) does, and firms must make that call inside the same 3-day window (FDA Guidance, §1d).
What Is an FDA Field Alert Report? The Three-Working-Day Deadline Explained
Around September 30, 2024, quality staff at Somerset Therapeutics' Bengaluru manufacturing site noticed something wrong with vials coming off a media fill line. Several were visibly cloudy, contamination anyone could see without a microscope. Federal regulation gave the company three working days to tell FDA. According to FDA, that report didn't go out until after a two-week inspection of the facility closed the following February, more than four months later.
That gap is now the subject of a September 4, 2025 warning letter. It's a useful entry point into a reporting mechanism most compliance teams outside regulatory affairs rarely think about closely.
What is a Field Alert Report?
A Field Alert Report, or FAR, is a report that holders of approved new drug applications (NDAs) and abbreviated new drug applications (ANDAs) must submit to FDA about problems with drug product already in distribution. The requirement lives in 21 CFR 314.81(b)(1), and it applies to any NDA/ANDA-approved product, including drug-device combinations, PET drugs, and designated medical gases (FDA Guidance, §1a).
Two categories of information trigger it:
| Element | Requirement |
|---|---|
| Trigger 1 | Any incident causing a drug product or its labeling to be mistaken for, or applied to, another article |
| Trigger 2 | Bacteriological contamination, any significant chemical, physical, or other change or deterioration in the distributed product, or failure of a distributed batch to meet its approved specifications |
| Who reports | The NDA/ANDA applicant, even when manufacturing or distribution is contracted out |
| Deadline | 3 working days from receipt of the information |
| Legal basis | 21 CFR 314.81(b)(1); FD&C Act § 505(k), 21 U.S.C. § 355(k) |
Source: FDA Field Alert Report Submission: Questions and Answers Guidance for Industry, July 2021.
When does the three-day clock actually start?
Not on confirmation. FDA's guidance is explicit: the clock starts "the date you received information of the kinds outlined in § 314.81(b)(1)," not the date a root cause is verified. The agency's own worked example: information identified on a Friday means the report is due by close of business the following Wednesday (FDA Guidance, §3a, §1f). A firm that spends weeks investigating before deciding whether to report has usually already blown the deadline. The guidance says so directly: even if a root cause is identified and corrected within the 3-day window, a FAR is still required.
Not every complaint clears the bar, either. FDA gives firms three working days just to evaluate a complaint against the trigger criteria, and a FAR is required only if that evaluation confirms the information fits 21 CFR 314.81(b)(1) (FDA Guidance, §1d).
Why a missed FAR isn't a minor paperwork issue
The consequence sits above simple lateness. FDA's guidance states plainly: failing to submit a required FAR within the time frame is, at minimum, a violation of 21 CFR 314.81(b)(1) and of FD&C Act section 505(k), 21 U.S.C. § 355(k). Violating section 505(k) is itself a prohibited act under section 301(e), 21 U.S.C. § 331(e). FDA may cite the failure as a Form FDA 483 observation, and a finding that a firm failed to report "may result in a regulatory action, whether or not the finding was cited on Form FDA 483" (FDA Guidance, §3b).
The Somerset Therapeutics letter
FDA's September 4, 2025 warning letter to Somerset Therapeutics Private Limited (MARCS-CMS 711340, Warning Letter 320-25-106) covers extensive CGMP citations tied to a February 10-21, 2025 inspection: inadequate investigation of a media fill contamination event, tape used to secure equipment inside an ISO 5 aseptic space, and multiple deficiencies in aseptic intervention design (FDA Warning Letter).
FDA calls out the FAR failure as its own violation, separate from the CGMP citations. The letter states the firm identified "visually cloudy vials" around September 30, 2024, and that "no FAR was submitted until after the close of this inspection," months past the three-working-day window. The letter also notes this specific FAR requirement, 21 CFR 314.81(b)(1)(ii), has been effective since May 23, 1985. It is not new. It is not ambiguous. It was not recently issued.
The rationale FDA gives for the deadline
FDA describes FARs as "an early warning system" meant to flag significant problems "in order to prevent potential safety hazards from drug products already in distribution and also to prevent potential safety hazards with drug products manufactured in the future" (FDA Warning Letter; FDA Guidance, Background). A quality investigation that takes months to complete is, by design, not supposed to be the trigger point. The FAR is supposed to arrive while the investigation is still open.
FAQ
Does every consumer complaint require a Field Alert Report?
No. Firms must evaluate complaints within three working days against the criteria in 21 CFR 314.81(b)(1). A FAR is required only if that evaluation confirms the complaint meets those criteria (FDA Guidance, §1d).
What if the root cause isn't known yet?
Submit an initial FAR with whatever information is available within the three-day window. FDA's guidance recommends follow-up and final FARs as an investigation develops, though only the initial FAR is mandatory (FDA Guidance, §1b, §6).
Is a FAR required for a product that was never distributed?
No. The requirement applies only to distributed drug products. An out-of-specification result on undistributed product does not, by itself, trigger a FAR (FDA Guidance, §1g).
Does filing a recall satisfy the FAR requirement?
No. A recall notification is not a substitute for a required FAR submission, even when the same underlying problem triggers both (FDA Guidance, §1k).
FDA's Field Alert Report deadline sits alongside a handful of other short-fuse compliance clocks that regulatory teams track separately from CGMP remediation work. Related reading: how long a company has to respond to an FDA Warning Letter, what CGMP actually requires under 21 CFR Parts 210 and 211, and how to read an FDA inspection classification.
Sources: 21 CFR 314.81 (eCFR), FDA: Field Alert Reports, FDA: Field Alert Report Submission: Questions and Answers Guidance for Industry, July 2021, FDA Warning Letter: Somerset Therapeutics Private Limited, MARCS-CMS 711340, September 4, 2025. Byline: The Argus Regulatory Analysis Team. Published 2026-07-16.